Do Cannabis Users Require More Anesthesia During Third Molar Removal Under Intravenous General Anesthesia When...

Cannabis users (CUs) may have higher intravenous general anesthetic (IVGA) requirements. It is unclear how cannabis exposure correlates with anesthetic requirements.

The primary purpose was to measure the association between cannabis exposure and total milligrams of propofol (TMP). The secondary purpose was to use cannabis exposure years (CEYs) and TMP for exposure risk stratification.

The investigators conducted a prospective study with a sample of subjects > 21 scheduled for third molar (M3) removal requiring at least one upper and lower M3 under IVGA between May 1, 2022, and February 28, 2023, at the University of Washington Oral and Maxillofacial Surgery (OMS) clinic. Exclusion criteria were subjects < 21, pregnant, previous substance use history, or who didn't qualify for IVGA.

The primary predictor variable was CEY, a continuous variable calculated by multiplying questionnaire responses for frequency (exposures per days, weeks, months, and years) and duration (weeks, months, and years).

The primary outcome variable was TMP (mg). Secondary outcome variables include stratifying cannabis exposure risk with TMP.

Covariates included age, sex, American Society Anesthesiology (ASA) classification, tobacco use, weight, body mass index (BMI), Mallampati score, number of M3s removed, and anesthesia and procedure times.

Independent t test, Fisher exact test, Pearson correlation coefficients, multivariate linear regression, and regression decision tree analysis were used. P values ≤ 0.05 were considered significant.

The sample was composed of 49 subjects with a mean age of 26.7 ± 5.5 years, 30 (61.2%) females, 38 (77.6%) CUs, and mean CEY 55.6 ± 50.2. Bivariate analysis showed a nonsignificant correlation between CEY and TMP (r = 0.3, P = .07). After adjusting confounders, CEY was significantly associated with TMP (coefficient = 0.7, 95% CI: 0.07 to 1.25, P = .03). Regression decision tree analysis stratified cannabis exposure based on TMP into 3 groups: 1) high risk (≥2 to 3 years, multiple daily use), 2) moderate risk (>2 to 3 years, infrequent use), and 3) low risk (<2 to 3 years, infrequent use).

Subjects reporting cannabis exposure ≥ 2 to 3 years of use with multiple daily sessions can be considered high risk for increased TMP for M3 removal.